Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 11/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863370 | 0.89 | LTA4H (0.61) | LTA4HCACNA1BHRH3KCNH2CACNA1H | |
| SCHEMBL5863728 | 0.84 | LTA4H (0.51) | LTA4HCACNA1BHRH3KDM4ESMN1; SMN2 | |
| SCHEMBL5863302 | 0.84 | LTA4H (0.47) | LTA4HCACNA1BHRH3KDM4EALDH1A1 | |
| SCHEMBL5864252 | 0.83 | MEN1 (0.55) | LTA4HKDM4EALDH1A1SMN1; SMN2DHFR | |
| SCHEMBL5863794 | 0.83 | LTA4H (0.46) | LTA4HCACNA1BHRH3KDM4EKCNH2 | |
| SCHEMBL5863641 | 0.82 | LTA4H (0.54) | LTA4HCACNA1BHRH3KCNH2CACNA1H | |
| SCHEMBL5863668 | 0.81 | KDR (0.60) | LTA4HHRH3SMN1; SMN2 | |
| SCHEMBL5863905 | 0.81 | DHFR (0.48) | KDM4EALDH1A1DHFR | |
| SCHEMBL5864113 | 0.76 | LTA4H (0.73) | LTA4HCACNA1BHRH3KCNH2CACNA1H | |
| SCHEMBL5863976 | 0.76 | LTA4H (0.73) | LTA4HCACNA1BHRH3CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | LTA4H 1687/4885CACNA1B 1176/4885HRH3 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.